Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future

被引：13
|
作者：
MacKenzie, Amy R. [1 ]
von Mehren, Margaret [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2007年 / 7卷 / 08期
关键词：
AP23573; bone sarcoma; CCI-779; mammalian target of rapamycin; RAD001; sirolimus; soft-tissue sarcoma;
D O I：
10.1586/14737140.7.8.1145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) is a protein kinase that plays a pivotal role in the control of cell growth and development. A part of the PI3K/Akt pathway, mTOR responds to growth factor stimuli as well as nutrient availability by variations in downstream phosphorylation. Increasing knowledge of the upstream regulators and downstream targets of mTOR has led to the development of anticancer drugs that suppress protein synthesis and metabolism. Rapamycin (sirolimus) and three rapamycin analogues are currently being evaluated in clinical trials: temsirolimus (CCI-779, Wyeth), everolimus (RAD001, Novartis Pharma AG), and AP23573 (Ariad Pharmaceuticals Inc.). This review will highlight the role of these inhibitors in the treatment of sarcoma.
引用
收藏
页码：1145 / 1154
页数：10
相关论文
共 50 条
  • [1] Mammalian target of rapamycin inhibition
    Dutcher, JP
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6382S - 6387S
  • [2] Mammalian Target of Rapamycin as the Therapeutic Target of Vascular Proliferative Diseases: Past, Present, and Future
    Huang, Wen-Qian
    Zou, Yan
    Tian, Ying
    Ma, Xiao-Feng
    Zhou, Qin-Yi
    Li, Zhen-Yu
    Gong, Shao-Xin
    Wang, Ai-Ping
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 79 (04) : 444 - 455
  • [3] Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis
    Huber, S.
    Bruns, C. J.
    Schmid, G.
    Hermann, P. C.
    Conrad, C.
    Niess, H.
    Huss, R.
    Graeb, C.
    Jauch, K-W
    Heeschen, C.
    Guba, M.
    KIDNEY INTERNATIONAL, 2007, 71 (08) : 771 - 777
  • [4] Mammalian target of rapamycin inhibition in hepatocellular carcinoma
    Ashworth, Rene E.
    Wu, Jennifer
    WORLD JOURNAL OF HEPATOLOGY, 2014, 6 (11) : 776 - 782
  • [5] New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma
    Agulnik, Mark
    CANCER, 2012, 118 (06) : 1486 - 1497
  • [6] Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
    Panwalkar, A
    Verstovsek, S
    Giles, FJ
    CANCER, 2004, 100 (04) : 657 - 666
  • [7] Inhibition of Mammalian Target of Rapamycin: The Janus Face of Immunosuppression?
    Soll, Christopher
    Clavien, Pierre-Alain
    HEPATOLOGY, 2010, 51 (04) : 1113 - 1115
  • [8] Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma
    Reis, Henning
    Hager, Thomas
    Wohlschlaeger, Jeremias
    Bauer, Sebastian
    Katenkamp, Kathrin
    Katenkamp, Detlef
    Baba, Hideo-Andreas
    HUMAN PATHOLOGY, 2013, 44 (10) : 2266 - 2274
  • [9] Mammalian target of rapamycin
    Meric-Bernstam, F
    Mills, GB
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 10 - 17
  • [10] Mechanisms of urokinase mediated activation of the mammalian target of rapamycin (mTOR)
    Davies, Mark G.
    Roztocil, Elisa
    Nicholl, Suzanne
    FASEB JOURNAL, 2007, 21 (05): : A192 - A192
12345